查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1703428

头孢克洛市场 - 全球产业规模、份额、趋势、机会和预测，按销售管道、最终用途、地区和竞争细分，2020-2030 年

Cefaclor Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球头孢克洛市场价值为 4.1819 亿美元，预计到 2030 年将达到 5.833 亿美元，预测期内的年复合成长率(CAGR) 为 3.77%。这一稳定的市场成长得益于头孢克洛（第二代头孢菌素抗生素）的广泛使用，该药物常用于治疗呼吸道感染、泌尿道感染、皮肤感染和其他细菌性疾病。头孢克洛的广谱功效、良好的安全性以及成熟的临床实用性继续支持其在门诊治疗环境中的强势地位。

市场概览
预测期 2026-2030
2024年市场规模 4.1819亿美元
2030年市场规模 5.833亿美元
2025-2030 年复合年增长率 3.77%
成长最快的领域 直接的
最大的市场 亚太

全球细菌感染发生率的上升、医疗保健意识的增强以及抗生素获取机会的增加（尤其是在发展中地区）进一步促进了市场的成长。值得注意的是，受医疗基础设施和城市化改善的推动，亚太和拉丁美洲市场的需求正在加速成长。同时，北美和欧洲由于拥有完善的医药分销网络和稳定的处方量，市场保持成熟。

儘管存在这些有利趋势，头孢克洛市场仍面临显着挑战。其中最主要的是人们对抗生素抗药性（AMR）的日益担忧以及实施严格的抗生素管理协议的监管压力。全球各地的卫生当局正在加强对抗生素使用的控制，以应对抗药性菌株的出现。虽然这些措施对于保障公众健康至关重要，但它们可能会影响头孢克洛的处方频率，并激励开发和采用新的抗菌替代品。

关键市场驱动因素

医疗保健产业扩张

主要市场挑战

抗生素抗药性（AMR）上升

主要市场趋势

细菌感染发生率上升

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球头孢克洛市场的影响

第五章：全球头孢克洛市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按销售管道（直接、间接）
    • 依最终用途（肺部感染、皮肤感染、耳部感染、咽喉感染、扁桃体感染、泌尿道感染、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美头孢克洛市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第七章：欧洲头孢克洛市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太头孢克洛市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章：南美洲头孢克洛市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十章：中东与非洲头孢克洛市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 产品发布（如有）
  • 最新动态

第 13 章：全球头孢克洛市场：SWOT 分析

第 14 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章：竞争格局

  • ACS DOBFAR
  • Qilu Antibiotics Pharmaceutical
  • Zhejiang Anglikang Pharmaceutical Co., Ltd.
  • Zhejiang Dongbang Pharmaceutical Co., Ltd.
  • Zhejiang East Asia Pharmaceutical Co., Ltd.
  • Zhejiang Zhebang Pharmaceutical Co., Ltd
  • Centrient Pharmaceuticals (Zibo)
  • Conscientia Industrial Co., Ltd
  • Dhanuka Laboratories Ltd.
  • Lupin Limited

第 16 章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 28248

Global Cefaclor market was valued at USD 418.19 million in 2024 and is projected to reach USD 583.30 million by 2030, expanding at a compound annual growth rate (CAGR) of 3.77% over the forecast period. This steady market growth is underpinned by the widespread use of cefaclor-a second-generation cephalosporin antibiotic-commonly prescribed for the treatment of respiratory tract infections, urinary tract infections, skin infections, and other bacterial conditions. Cefaclor's broad-spectrum efficacy, favorable safety profile, and established clinical utility continue to support its strong positioning in outpatient therapeutic settings.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 418.19 Million
Market Size 2030USD 583.30 Million
CAGR 2025-20303.77%
Fastest Growing SegmentDirect
Largest MarketAsia-Pacific

Market growth is further reinforced by the rising global incidence of bacterial infections, increasing healthcare awareness, and enhanced access to antibiotics-particularly in developing regions. Notably, markets in Asia-Pacific and Latin America are experiencing accelerated demand, driven by improvements in healthcare infrastructure and urbanization. Meanwhile, North America and Europe maintain mature markets due to well-established pharmaceutical distribution networks and stable prescription volumes.

Despite these favorable trends, the cefaclor market faces notable challenges. Chief among them are the growing concerns surrounding antimicrobial resistance (AMR) and regulatory pressures to implement stringent antibiotic stewardship protocols. Health authorities across the globe are enforcing tighter controls on antibiotic use to counter the emergence of resistant bacterial strains. While these initiatives are critical for safeguarding public health, they may impact the prescribing frequency of cefaclor and incentivize the development and adoption of newer antimicrobial alternatives.

Key Market Drivers

Healthcare Sector Expansion

The continued expansion of the global healthcare sector remains a key driver of cefaclor market growth. The global hospital market is projected to generate approximately USD 4.41 trillion in revenue by 2025, with the United States expected to contribute USD 1.55 trillion. In parallel, U.S. hospitals are significantly investing in telemedicine to broaden healthcare access-especially in rural and underserved communities.

Emerging economies are witnessing similar trends, with growing investments in healthcare infrastructure fueling demand for widely used antibiotics such as cefaclor. For instance, India's Union Budget 2025-26 allocated USD 11.50 billion toward healthcare, emphasizing system development and capacity building. The government also plans to launch a USD 6.80 billion credit incentive scheme to attract further investments into healthcare infrastructure.

These public and private sector investments are facilitating the expansion of hospitals, diagnostic services, and healthcare personnel. As access to medical care improves-particularly in previously underserved regions-diagnosis and treatment rates are rising, thereby driving higher prescription volumes of broad-spectrum antibiotics like cefaclor.

Key Market Challenges

Rising Antimicrobial Resistance (AMR)

The global escalation of antimicrobial resistance (AMR) presents a significant barrier to the growth of the cefaclor market. Resistance among bacterial strains is reducing the clinical effectiveness of widely used antibiotics, including second-generation cephalosporins such as cefaclor. This trend not only compromises treatment outcomes but also dampens overall demand for the drug.

AMR has become a major global health concern, fueled by the overuse and inappropriate prescription of antibiotics in both human healthcare and agriculture. In many regions, antibiotics like cefaclor are frequently administered without adequate diagnostic justification or are misused for viral infections, accelerating the emergence of resistant strains. Consequently, the therapeutic reliability of cefaclor for treating infections such as bronchitis, otitis media, and urinary tract infections is increasingly being called into question.

Key Market Trends

Rising Incidence of Bacterial Infections

The increasing prevalence of bacterial infections represents a significant trend shaping the cefaclor market. The 2024 WHO Bacterial Priority Pathogens List (BPPL) highlights 24 high-risk pathogens across 15 bacterial families, including Gram-negative bacteria resistant to last-resort antibiotics and drug-resistant strains such as Mycobacterium tuberculosis, Salmonella, Shigella, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Staphylococcus aureus.

These pathogens have been identified as global threats due to their high transmission potential, limited treatment options, and widespread burden. In this context, cefaclor continues to be a vital therapeutic agent, especially in addressing respiratory tract infections, skin infections, otitis media, and urinary tract infections.

The surge in treatable respiratory infections-such as pharyngitis, bronchitis, and pneumonia-is particularly notable among pediatric and elderly populations, where immune vulnerability is greater. As healthcare systems respond to seasonal infection cycles and the ongoing repercussions of recent viral pandemics, the demand for reliable, broad-spectrum antibiotics like cefaclor remains robust.

Key Market Players

  • ACS DOBFAR
  • Qilu Antibiotics Pharmaceutical
  • Zhejiang Anglikang Pharmaceutical Co., Ltd.
  • Zhejiang Dongbang Pharmaceutical Co., Ltd.
  • Zhejiang East Asia Pharmaceutical Co., Ltd.
  • Zhejiang Zhebang Pharmaceutical Co., Ltd
  • Centrient Pharmaceuticals (Zibo)
  • Conscientia Industrial Co., Ltd
  • Dhanuka Laboratories Ltd.
  • Lupin Limited

Report Scope

In this report, the Global Cefaclor Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cefaclor Market, By Sales Channel:

  • Direct
  • Indirect

Cefaclor Market, By End Use:

  • Lung Infection
  • Skin Infection
  • Ear Infection
  • Throat Infection
  • Tonsils
  • Urinary Tract Infection
  • Others

Cefaclor Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cefaclor Market.

Available Customizations:

Global Cefaclor Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Cefaclor Market

5. Global Cefaclor Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Lung Infection, Skin Infection, Ear Infection, Throat Infection, Tonsils, Urinary Tract Infection, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Cefaclor Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cefaclor Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Cefaclor Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Cefaclor Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Cefaclor Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Cefaclor Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Cefaclor Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Cefaclor Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Cefaclor Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Cefaclor Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Cefaclor Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cefaclor Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Cefaclor Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Cefaclor Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Cefaclor Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Cefaclor Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Cefaclor Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cefaclor Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Cefaclor Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Cefaclor Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Cefaclor Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cefaclor Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Cefaclor Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Cefaclor Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cefaclor Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. ACS DOBFAR
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Qilu Antibiotics Pharmaceutical
  • 15.3. Zhejiang Anglikang Pharmaceutical Co., Ltd.
  • 15.4. Zhejiang Dongbang Pharmaceutical Co., Ltd.
  • 15.5. Zhejiang East Asia Pharmaceutical Co., Ltd.
  • 15.6. Zhejiang Zhebang Pharmaceutical Co., Ltd
  • 15.7. Centrient Pharmaceuticals (Zibo)
  • 15.8. Conscientia Industrial Co., Ltd
  • 15.9. Dhanuka Laboratories Ltd.
  • 15.10. Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer